SFX by Ex Libris Inc.

Title:	Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium
Source:	Clinical Pharmacology & Therapeutics [0009-9236] Varin, France yr:1990

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Cheymol, G. "Effects of obesity on pharmacokinetics implications for drug therapy." Clinical pharmacokinetics 39.3 (2000): 215-31.
description	2.	Hanley, Michael J. "Effect of obesity on the pharmacokinetics of drugs in humans." Clinical Pharmacokinetics 49.2 (2010): 71-87.
description	3.	Bearden, D T T. "Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics." Clinical pharmacokinetics 38.5 (2000): 415-26.
description	4.	Leykin, Y. "Pharmacokinetic considerations in the obese." Bailliere's best practice & research. Clinical anaesthesiology 25.1 (2011): 27-36.
description	5.	Miller, April D D. "Medication and nutrient administration considerations after bariatric surgery." American journal of health-system pharmacy 63.19 (2006): 1852-1857.
description	6.	Casati, A. "Anesthesia in the obese patient: Pharmacokinetic considerations." Journal of clinical anesthesia 17.2 (2005): 134-145.
description	7.	Bearden, David T T. "Antimicrobial dosing considerations in obese adult patients." Pharmacotherapy 27.8 (2007): 1081-91.
description	8.	JE, M. "Impact of Obesity on Drug Metabolism and Elimination in Adults and Children." Clinical pharmacokinetics 51.5 (2012): 277-304.
description	9.	Morrish, Glynn A. "The effects of obesity on drug pharmacokinetics in humans." Expert Opinion on Drug Metabolism and Toxicology 7.6 (2011): 697-706.
description	10.	Wurtz, G. "Antimicrobial dosing in obese patients." Clinical infectious diseases 25.1 (1997): 112-8.
description	11.	Smith, A. "Pharmacokinetic considerations in Roux-en-Y gastric bypass patients." American journal of health-system pharmacy 68.23 (2011): 2241-2247.
description	12.	Jain, R. "Implications of Obesity for Drug Therapy: Limitations and Challenges." Clinical pharmacology & therapeutics 90.1 (2011): 77-89.
description	13.	Lemmens, Hendrikus J. "Perioperative pharmacology in morbid obesity." Current opinion in anaesthesiology 23.4 (2010): 485-491.
description	14.	Sharma, R. M. "A systematic review of drug absorption following bariatric surgery and its theoretical implications." Obesity reviews 11.1 (2009): 41-50.
description	15.	Decker, G. Anton n. "Gastrointestinal and nutritional complications after bariatric surgery." The American journal of gastroenterology 102.11 (2007): 2571-80.
description	16.	Curran, Sheridan P. "Orlistat: A review of its use in the management of patients with obesity." Drugs 64.24 (2004): 2845-2864.
description	17.	Voelker, M. "Nursing challenges in the administration of oral antidepressant medications in gastric bypass patients." Journal of perianesthesia nursing 22.2 (2007): 108-24.
description	18.	Edmiston, Charles E E. "Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeutic levels?" Surgery 136.4 (2004): 738-47.
description	19.	Slawson, Matthew H H. "Quantitative analysis of selegiline and three metabolites (N-desmethylselegiline, methamphetamine, and amphetamine) in human plasma by high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry." Journal of analytical toxicology 30.4 (2002): 430-7.
description	20.	Shibutani, K. "Accuracy of pharmacokinetic models for predicting plasma fentanyl concentrations in lean and obese surgical patients: derivation of dosing weight ("pharmacokinetic mass")." Anesthesiology 101.3 (2004): 603-13.